These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1113 related articles for article (PubMed ID: 36951829)

  • 21. Effectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans : A Target Trial Emulation.
    Ioannou GN; Berry K; Rajeevan N; Li Y; Mutalik P; Yan L; Bui D; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Bajema KL
    Ann Intern Med; 2023 Nov; 176(11):1486-1497. PubMed ID: 37903369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early Adoption of Anti-SARS-CoV-2 Pharmacotherapies Among US Veterans With Mild to Moderate COVID-19, January and February 2022.
    Bajema KL; Wang XQ; Hynes DM; Rowneki M; Hickok A; Cunningham F; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Viglianti EM; Streja E; Yan L; Aslan M; Huang GD; Ioannou GN
    JAMA Netw Open; 2022 Nov; 5(11):e2241434. PubMed ID: 36367727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risks and burdens of incident diabetes in long COVID: a cohort study.
    Xie Y; Al-Aly Z
    Lancet Diabetes Endocrinol; 2022 May; 10(5):311-321. PubMed ID: 35325624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics and Outcomes of US Veterans With Immunocompromised Conditions at High Risk of SARS-CoV-2 Infection With or Without Receipt of Oral Antiviral Agents.
    Gentry CA; Nguyen PN; Thind SK; Kurdgelashvili G; Williams RJ
    Clin Infect Dis; 2024 Feb; 78(2):330-337. PubMed ID: 37619991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rates and Factors Associated With Documentation of Diagnostic Codes for Long COVID in the National Veterans Affairs Health Care System.
    Ioannou GN; Baraff A; Fox A; Shahoumian T; Hickok A; O'Hare AM; Bohnert ASB; Boyko EJ; Maciejewski ML; Bowling CB; Viglianti E; Iwashyna TJ; Hynes DM
    JAMA Netw Open; 2022 Jul; 5(7):e2224359. PubMed ID: 35904783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents.
    Gentry CA; Nguyen P; Thind SK; Kurdgelashvili G; Williams RJ
    J Infect; 2023 Mar; 86(3):248-255. PubMed ID: 36702309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina.
    Henderson HI; Wohl DA; Fischer WA; Bartelt LA; van Duin D; Agil DM; Browne LE; Li KP; Moy A; Eron JJ; Napravnik S
    J Antimicrob Chemother; 2024 Apr; 79(4):859-867. PubMed ID: 38380946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health Care Utilization in the 6 Months Following SARS-CoV-2 Infection.
    Tartof SY; Malden DE; Liu IA; Sy LS; Lewin BJ; Williams JTB; Hambidge SJ; Alpern JD; Daley MF; Nelson JC; McClure D; Zerbo O; Henninger ML; Fuller C; Weintraub E; Saydah S; Qian L
    JAMA Netw Open; 2022 Aug; 5(8):e2225657. PubMed ID: 35960522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Effectiveness of Nirmatrelvir/Ritonavir on Coronavirus Disease 2019-Associated Hospitalization Prevention: A Population-based Cohort Study in the Province of Quebec, Canada.
    Kaboré JL; Laffont B; Diop M; Tardif MR; Turgeon AF; Dumaresq J; Luong ML; Cauchon M; Chapdelaine H; Claveau D; Brosseau M; Haddad E; Benigeri M
    Clin Infect Dis; 2023 Sep; 77(6):805-815. PubMed ID: 37149726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.
    Evans A; Qi C; Adebayo JO; Underwood J; Coulson J; Bailey R; Lyons R; Edwards A; Cooper A; John G; Akbari A
    J Infect; 2023 Apr; 86(4):352-360. PubMed ID: 36773891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia.
    Low EV; Pathmanathan MD; Ten YY; Chidambaram SK; Kim WR; Lee WJ; Teh ZW; Appannan MR; Ismail M; Samad AA; Peariasamy KM
    BMC Infect Dis; 2024 Aug; 24(1):780. PubMed ID: 39103829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation.
    Wong CKH; Lau KTK; Chung MSH; Au ICH; Cheung KW; Lau EHY; Daoud Y; Cowling BJ; Leung GM
    Nat Med; 2024 Jan; 30(1):112-116. PubMed ID: 37913816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long COVID after breakthrough SARS-CoV-2 infection.
    Al-Aly Z; Bowe B; Xie Y
    Nat Med; 2022 Jul; 28(7):1461-1467. PubMed ID: 35614233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data.
    Petrakis V; Rafailidis P; Trypsianis G; Papazoglou D; Panagopoulos P
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of Initial SARS-CoV-2 Test Positivity With Patient-Reported Well-being 3 Months After a Symptomatic Illness.
    Wisk LE; Gottlieb MA; Spatz ES; Yu H; Wang RC; Slovis BH; Saydah S; Plumb ID; O'Laughlin KN; Montoy JCC; McDonald SA; Lin Z; Lin JS; Koo K; Idris AH; Huebinger RM; Hill MJ; Gentile NL; Chang AM; Anderson J; Hota B; Venkatesh AK; Weinstein RA; Elmore JG; Nichol G;
    JAMA Netw Open; 2022 Dec; 5(12):e2244486. PubMed ID: 36454572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rates of ICD-10 Code U09.9 Documentation and Clinical Characteristics of VA Patients With Post-COVID-19 Condition.
    Wander PL; Baraff A; Fox A; Cho K; Maripuri M; Honerlaw JP; Ho YL; Dey AT; O'Hare AM; Bohnert ASB; Boyko EJ; Maciejewski ML; Viglianti E; Iwashyna TJ; Hynes DM; Osborne TF; Ioannou GN
    JAMA Netw Open; 2023 Dec; 6(12):e2346783. PubMed ID: 38064215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and Characteristics Associated With Post-COVID-19 Condition Among Nonhospitalized Adolescents and Young Adults.
    Selvakumar J; Havdal LB; Drevvatne M; Brodwall EM; Lund Berven L; Stiansen-Sonerud T; Einvik G; Leegaard TM; Tjade T; Michelsen AE; Mollnes TE; Lund-Johansen F; Holmøy T; Zetterberg H; Blennow K; Sandler CX; Cvejic E; Lloyd AR; Wyller VBB
    JAMA Netw Open; 2023 Mar; 6(3):e235763. PubMed ID: 36995712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COVID-19 mRNA vaccine effectiveness against hospitalisation and death in veterans according to frailty status during the SARS-CoV-2 delta (B.1.617.2) variant surge in the USA: a retrospective cohort study.
    Tang F; Hammel IS; Andrew MK; Ruiz JG
    Lancet Healthy Longev; 2022 Sep; 3(9):e589-e598. PubMed ID: 35935474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perceived Cognitive Deficits in Patients With Symptomatic SARS-CoV-2 and Their Association With Post-COVID-19 Condition.
    Liu TC; Yoo SM; Sim MS; Motwani Y; Viswanathan N; Wenger NS
    JAMA Netw Open; 2023 May; 6(5):e2311974. PubMed ID: 37145596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.